newsfilter
← Latest News
GlobeNewswire·

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

Data from the Phase 1 CARLYSLE study in severe refractory systemic lupus erythematosus (srSLE) suggests obe-cel is well tolerated with no ICANS or high-grade CRS; 50 million cell dose selected for Phase 2 pivotal